Generating evidence for diagnosis and therapy of RarE LIVEr disease: the RELIVE Initiative for...
FOR IMMEDIATE RELEASE
Generating evidence for diagnosis and therapy of RarE LIVEr disease: the RELIVE Initiative for systematic reviews and meta-analyses
November 9, 2022
HEIDELBERG, GERMANY – On November 3, 2022, Liver Surgery Research’s new article, “Generating evidence for diagnosis and therapy of RarE LIVEr disease: the RELIVE Initiative for systematic reviews and meta-analyses," authored by Juri Fuchs, Anastasia Murtha-Lemekhova, Jan Pfeiffenberger, Alexander Fichtner, Patrick Günther, Niels Halama, Philipp Mayer, Daniel Hornuss, Rosa Klotz, Pascal Probst & Katrin Hoffmann was published. This manuscript was published by the peer reviewed and open access journal, Systematic Reviews (BMC, Springer Nature); which has an impact factor of 3.136.
Background: Rare liver lesions and diseases have seldomly aroused major interest of researchers. For most guidelines, presumably similar clinical conditions are pooled without detailed investigations of singularities that they present.
Main Text: A multidisciplinary project aiming to establish evidence-based therapies for rare liver diseases has been founded. A series of systematic reviews and meta-analyses will be the starting point for a structured development of guidelines for rare conditions of the liver affecting pediatric and adult populations. The novel approach will be focusing on case reports and small patient series with distinct rare liver diseases without pooling several presumably acceptably similar conditions. Thus, a vital resource of information will be utilized, which has been largely neglected hitherto.
Conclusion: Highly specific recommendations based on highest available evidence will therefore be developed for specific conditions, advancing the individualized medicine approach for the afflicted patients. To learn more about this study, visit https://www.nature.com/articles/s41598-022-16968-9#citeas
About Liver Surgery Research
Liver Surgery Research (LSR) is a medical research group, located at Heidelberg University in Heidelberg, Germany. LSR specializes in research investigating liver regeneration after hepatectomy (liver resection) and post-hepatectomy liver failure, HCC development and treatment (especially in the context of MAFLD [metabolically associated fatty liver disease]), and rare liver lesions and diseases. LSR is the founder and leader of the RELIVE (RarE LIVEr) Initiative; a multidisciplinary project to establish evidence-based therapies for rare liver diseases. LSR is currently working on over 20 research projects and has over 100 peer reviewed published authorships. To learn more about Liver Surgery Research, visit www.liversurgeryresearch.com.
Liver Surgery Research at Heidelberg University
Fuchs, J., Murtha-Lemekhova, A., Pfeiffenberger, J. et al. Generating evidence for diagnosis and therapy of RarE LIVEr disease: the RELIVE Initiative for systematic reviews and meta-analyses. Syst Rev 11, 235 (2022). https://doi.org/10.1186/s13643-022-02105-0